Ravulizumab was successful in improving blood health, kidney function and quality of life while maintaining eGFR in pediatric and adult patients with atypical hemolytic uremic syndrome, according ...

The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with ...